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Summary
Major histocompatibility complex (MHC) variation is a
key determinant of susceptibility and resistance to a large
number of infectious, autoimmune and other diseases.
Identiﬁcation of the MHC variants conferring susceptibility
to disease is problematic, due to high levels of variation and
linkage disequilibrium. Recent cataloguing and analysis
of variation over the complete MHC has facilitated
localization of susceptibility loci for autoimmune diseases,
and provided insight into the MHC’s evolution. This
review considers how the unusual genetic characteristics
of the MHC impact on strategies to identify variants
causing, or contributing to, disease phenotypes. It also
considers the MHC in relation to novel mechanisms
inﬂuencing gene function and regulation, such as
epistasis, epigenetics and microRNAs. These developments,
along with recent technological advances, shed light on
genetic association in complex disease.
Introduction
The classical major histocompatibility complex (MHC)
spans ~4  Mb and comprises over 160 protein-coding
genes. Compared with other similar-sized sections of the
human genome, the MHC holds the most, and some of
the longest recognized associations with disease. The
MHC inﬂuences numerous chronic inﬂammatory and
autoimmune conditions, including type I diabetes,
multiple sclerosis and Crohn’s disease. MHC variants also
confer susceptibility to many infectious diseases, such as
malaria and HIV. However, for most diseases the precise
genetic components and mechanisms involved remain
undeﬁned. The genetic basis of phenotypic traits within
the MHC has been analysed in terms of several principle
axes, including epistasis, penetrance, phenotypic
plasticity, pleiotropy and polygeny. These underscore the
complexity in resolving genetic effects within the MHC
and relate largely to its unique evolutionary history.
The MHC, which possibly originated as a rudimentary
protochordate histocompatibility locus (De Tomaso et al.,
2005), has evolved over many millions of years to become
a master coordinator of speciﬁcity in both adaptive and
innate immune systems. This responsibility may explain
some distinctive features of the MHC, such as high gene
density and diversity, and low recombination. Yet it is
these features together with the complex aetiology of
multifactorial MHC-linked diseases and frequent non-
Mendelian inheritance that hamper precise identiﬁcation
of variants contributing to disease phenotypes. In
addition to being one of the most gene-dense regions of
our genome, the MHC is one of the most variable. This
diversity is a major contributor to individual differences in
immune responsiveness.
In relation to complex diseases, the MHC’s importance
was recently conﬁrmed and emphasized by whole-genome
association (WGA) studies (WTCCC, 2007). The
strongest associations were found with the autoimmune
diseases type 1 diabetes and rheumatoid arthritis. Another
WGA study demonstrated that the three major determi-
nates for host control of HIV-1 are also contained within
the MHC, serving as testimony to its further role in
conferring resistance to infectious diseases (Fellay et al.,
2007).
Many genetic risk variants in the MHC are common,
suggesting that they bestow a past, or possibly enduring,
evolutionary advantage. Consequently, a high proportion
of individuals carry genetic risk factors for complex
disease, however, the majority are healthy because of low
penetrance and/or the combination of genetic and
environmental risk factors required are incomplete.
Substantial evidence supports pathogen-driven
balancing selection as a major force driving and maintaining
human leucocyte antigen (HLA) diversity. This hypothesis
is supported by a recent study which showed that
populations from areas with high pathogen diversity have
increased HLA diversity relative to their average genomic
diversity (Prugnolle et al., 2005). Furthermore, other
mechanisms may also be involved, such as MHC-dependent
mate selection and preferential abortion (Apanius et al.,
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1997; Yamazaki & Beauchamp, 2007). Despite medical
progress, pathogen-imposed selectivity must be high as
infectious disease causes 50% of global mortality among
those below the age of 45 (Kapp, 1999).
Characterization of HLA loci was initially motivated by
their importance in transplantation. Subsequently, the
typing of classical HLA genes and microsatellites,
followed by variation at non-HLA candidate loci, was
exploited to study MHC involvement in disease. Over
time, conﬁdence that the HLA genes act as predominant
disease determinants within the MHC was established,
although a small number of non-HLA genes have been
identiﬁed as directly causative of some diseases. However,
uncertainty still remains to which HLA genes are primarily
important and to whether, or to what extent, non-HLA
loci contribute to disease phenotypes.
Recently, systematic DNA sequence analyses between
haplotypes have yielded information on polymorphisms
and ﬁne-structure linkage disequilibrium (LD) across the
complete MHC. This information provides pools of
sequence variants for disease association analysis. It
also showed insight into the evolutionary dynamics and
ancestral origins of common HLA loci and their haplo-
types. However, there is an increasing ‘postgenomic’
appreciation of the intricacies of genome structure in
modulating gene activities. Novel areas of research
include chromatin modiﬁcations and microRNAs. The
challenge now is to determine the role of these control
mechanisms in the cellular development of a disease. This
review surveys the genetic architecture of the MHC, its
relationship with disease, and how it impacts on strategies
to identify variants contributing to common, multifactorial
disorders.
MHC diversity
With HLA coding variation well characterized, attention
has turned to the MHC region as a whole for additional
information on variability relevant to disease. Recently,
four independent re-sequencing projects have signiﬁcantly
expanded our knowledge of variation within the MHC
(Raymond et al., 2005; Shiina et al., 2006; Smith et al., 2006;
Horton et al., 2008). The aims, target area, haplotype
depth and strategies differed between projects. The
strategies included shotgun sequencing of fosmid and
bacterial artiﬁcial chromosome (BAC) libraries, as
well as polymerase chain reaction (PCR)-based, direct
sequencing, allowing detection of rare variants. The
MHC haplotype project (Horton et al., 2008) determined
the sequences of eight common and disease-associated
MHC haplotypes. These serve as single haplotype
reference sequences and can be viewed in the context of
current genome annotation through the VEGA genome
browser (Fig. 1).
The comprehensive catalogue of variation generated by
these projects allowed the construction of high-resolution
LD maps (Miretti et al., 2005; de Bakker et al., 2006b)
and facilitated precise mapping of susceptibility loci for
multiple sclerosis (Yeo et al., 2007) and type I diabetes
(Nejentsev et al., 2007). The amassed data also draw a
detailed picture of the degree and distribution of variation
across the MHC as well as allowing genealogical relation-
ships between haplotypes to be deﬁned. Divergence
between some pairs of haplotypes over parts of class I and
class II can be 20-fold higher than the rest of the genome,
consistent with independent haplotype evolution over
tens of millions of years (assuming normal mutation
rates). These extreme levels of haplotype divergence
remain unprecedented in the human genome. Remarkably,
human–human pairwise divergences within the MHC can
be higher than human–primate comparisons (Raymond
et al., 2005). Typically, regions of the MHC distant from
classical HLA genes show the lowest levels of variation, in
line with the average across the genome. However, areas
of exceptional divergence (> 3%) are not limited to HLA
loci, but spread over tens of thousands of base pairs into
the surrounding regions. The observed broad peaks of
variation may have arisen from the combined effects of
balancing selection acting on the peptide-binding
domains of HLA loci with hitchhiking of neighbouring
neutral mutations. A novel, but untested, hypothesis
proposes that some MHC-linked diseases are a conse-
quence of hitchhiked deleterious mutations within nearby
genes (Shiina et al., 2006). A recent study suggests that
new alleles in HLA loci are being recurrently created by
gene conversion (von Salome et al., 2007).
Regulatory regions of MHC genes may also be subject
to natural selection (Liu et al., 2006; Loisel et al., 2006;
Yamazaki & Beauchamp, 2007), where sequence variants
conferring differential levels of expression among dif-
ferent cells or in different developmental stages may be the
selected factors. It is predicted from recent large-scale
expression analyses that variants in regulatory regions
may play a greater contribution to complex disease than
previously thought (Spielman et al., 2007). Genetic vari-
ants that modify HLA-DR, HLA-DQ, HLA-DP, HLA-A
and HLA-C have been identiﬁed (Dixon et al., 2007). The
strength of the observed effects implies that associations
of MHC class I and II polymorphism with disease may
relate to the level of gene expression as much as the restriction
of response to antigen. Characterization of regulatory
region architecture and transcriptional regulation of
MHC genes may therefore elucidate the molecular basis
for some MHC associations to diseases and particular
immune responses (Eagle et al., 2006; Baena et al., 2007;
Rodriguez-Rodero  et al., 2007; Venkataraman et al.,
2007). Moreover, other variation not associated with the
peptide-binding grooves, such as that affecting the cyto-
plasmic tail of HLA molecules, may be critical as it alters
their export to the cell surface (Boyle et al., 2006).
MHC genetic variation also affects alternative splicing,
which expands the information content and versatility of
the transcriptome through the expression of multiple
different mRNAs from individual genes (Rollinger-
Holzinger  et al., 2000; Boyle et al., 2007; Greetham
et al., 2007). Current annotation of the MHC reference
sequence (PGF) indicates that the total number of splice
variants is almost fourfold higher than the total number ofMHC architecture, evolution and disease 181
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loci (Horton et al., 2008). Some MHC loci possess over
20 splice variants, e.g. BAT1/3 and LST1 (VEGA). At
least eight MHC loci are known to exhibit haplotypic
variation at their splice sites, which may affect expression
at the post-transcriptional level (Kralovicova et al., 2004;
Traherne et al., 2006a; Horton et al., 2008). A signiﬁcant
proportion of sequence variation outside splice sites is
also likely to affect splicing efﬁciency (Hull et al., 2007).
A growing number of reports are identifying disease-
susceptibility alleles, across the genome, that are associated
with speciﬁc splicing patterns (Wang & Cooper, 2007).
Alterations in splicing can be directly causative, modify
severity or be linked with disease susceptibility. Full
characterization of the MHC transcriptome and splicing
code is therefore likely to provide new insights, and useful
diagnostic and prognostic tools for MHC-linked diseases.
Gene clustering
The MHC is one of the most gene-dense regions of the
genome. One explanation for this is that the region
favours high levels of expression (Horton et al., 2004). It
contains a disproportionately high number of immune-
system genes (Fig. 2). Possible advantages of clustering of
Figure 1. Annotation of MHC reference haplotypes in VEGA. Representation of the PGF, COX and QBL haplotypes and variation in the Vega Genome 
Browser ‘MultiContigView’. MultiContigView allows simultaneous display and navigation of genome annotation between the human MHC regions 
in the different reference haplotypes. Manually curated gene structures within the HLA-DR region are shown (see Fig. 3 and accompanying text).182 J. A. Traherne
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immune-system genes in the MHC include enhanced
coordination of gene expression and facilitated sequence
exchange among sequence-related gene duplicates
(paralogues). Gene families can rapidly diversify by
recombination and sequence exchange, making them
especially adaptable evolutionarily. A concept expanded
on below proposes that clustering of polymorphic genes
may help to account for marked LD within the MHC.
Structural variation
Recent advances in global genome-wide analysis have
revealed abundant and variable segmental duplications of
genomic regions among different individuals, highlighting
structural and interindividual copy number variation
(CNV) as an important source of genetic diversity in
relation to disease (Conrad et al., 2006; Redon et al.,
2006; Wong et al., 2007). Two regions of the MHC
associated with disease have long been conﬁrmed to have
gene CNVs. The ﬁrst is in the class II region between
HLA-DRB1 and HLA-DRB9  (a non-functional gene
segment) that in some haplotypes houses one additional
functional  DRB gene (HLA-DRB3,  HLA-DRB4 or
HLA-DRB5), and one, two or no additional copies of
HLA-DRB pseudogenes (HLA-DRB2,  HLA-DRB6,
HLA-DRB7 or HLA-DRB8). The second region is the
tandem duplication in the class III region termed the
RCCX (RP-C4-CYP21-TNX) module, which contains a
gene for complement component C4. In addition to a C4
gene, each duplicated module includes a disrupted
sequence (CYP21A pseudogene) for the steroid cyto-
chrome P450 21-hydroxylase (CYP21B) gene (Chung
et al., 2002). A single MHC haplotype can contain one to
four copies of the RCCX module (Chung et al., 2002)
(Fig. 3).
Sequence exchange (gene conversion) among variants
of RCCX modules is a mechanism that has generated
diversity and has introduced deleterious mutations with
pathological consequence. For example, mutations of
CYP21A transferred to CYP21B are the primary cause of
congenital hyperplasia (Friaes et al., 2006; Lee et al., 2006).
Sequence duplications of related CNVs are highly
homologous but generally do not share identical DNA
sequence. Close examination often reveals additional
genetic events that result in new polymorphisms adding
new functions to existing gene products. In the case of the
RCCX, the breakpoint(s) of duplication are identical
among duplicated modules, but secondary genetic diver-
siﬁcations have led to the emergence of two forms of C4
genes (short and long, the size difference resulting from
the integration of the endogenous retrovirus HERV-K into
its ninth intron) and two isotypes of C4 proteins (C4A
and C4B), each with multiple allotypes.
Gene CNV can result in differential levels of gene
expression and by this means could account for a signiﬁ-
cant proportion of phenotypic variation in human health
Figure 2. A reduced map of the MHC illustrating clustering of immune system genes. Two kinds of gene clustering are apparent. First, sequence-
related duplicates that have allowed diversiﬁcation of duplicates, e.g. HLA or C4 complement genes. Second, sequence unrelated genes with related 
immune function, e.g. PSMB8/9 — proteosome components, TAP1/2 — peptide transporters, TAPBP — peptide chaperone, and HLA — peptide 
presentation.MHC architecture, evolution and disease 183
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and disease (Gonzalez et al., 2005; Aitman et al., 2006;
Fellermann et al., 2006). Pertinent in this regard are the
strong correlations of C4 gene CNV with human systemic
lupus erythematosus (SLE), from a recent study (Yang
et al., 2007). A dose-dependent effect was seen; from
increased SLE disease risk at low copy number, to protection
against disease susceptibility at high copy number. Typical
of many susceptibility genes associated with an auto-
immune disease, the risk factor (low copy number of C4)
is present in the general population, but the prevalence
is signiﬁcantly increased in the patient population.
In addition to the above structural variation, many
polymorphisms resulting from presence/absence of
retroviral sequences (e.g. Alu, LINE, HERV, LTR, MER
and SVA) have been observed among MHC haplotypes.
The retroviral insertions are often located either in the
HLA-DR region or near the classical HLA class I genes.
The signiﬁcance of their targeting to HLA regions is
unclear, although their presence may promote molecular
evolution by facilitating non-homologous recombination
or gene conversion events (Stewart et al., 2004; Wurtele
et al., 2005; Sen et al., 2006; Zhi, 2007). Intriguingly, a
recent study highlights the possibility that a HERV-
derived gene, HCP5, located at < 100 kb from HLA-B,
may contribute to host control of HIV-1 attributed to
allele B*57 (Fellay et al., 2007).
Recombination
MHC divergence patterns indicate that evolutionarily
successful recombination events have been infrequent
compared to the genome as a whole. Recombination ﬂuc-
tuates greatly across the region, but overall MHC recom-
bination is considerably lower compared with the genome
average (Miretti et al., 2005; The International HapMap
Consortium, 2005; de Bakker et al., 2006b). In other
words, many combinations of alleles at MHC genes rarely
become separated over long periods of evolution. One
interpretation is to suppose that certain MHC genes are
tuned to work together, as a set of alleles on a particular
haplotype (interactions between DNA sites in cis). Hence,
the absence of detectable recombination may reﬂect
maintenance of allele combinations with favoured
immunological function through selection against
unfavourable recombinant haplotypes. The MHC con-
tains many polymorphic genes, encoding products with
related functions (e.g. PSMB8/9 — proteosome components;
TAP1/2 — peptide  transporters;  TAPBP — peptide  chaper-
one; HLA — peptide presentation) or components (e.g.
HLA-DQA and HLA-DQB). It therefore seems appro-
priate that such genes are inherited as a coordinated set.
The notion of genetic interaction (epistasis) within the
MHC is expanded on below.
Although preferred combinations of alleles are conceiv-
ably the decisive determinant of haplotype selection, it
may also have arisen through recombination suppression
in regions of high divergence (Shen & Huang, 1989). The
extent of reduced recombination rate acting on diverged
haplotypes could be assessed by high-resolution recombi-
nation analysis of sperm typing. This experiment would
help resolve the question of whether haplotype divergence
is predominantly the effect or the cause of the prevailing
patterns of allelic association. Also warranting further
investigation are sequence inversions, which can be difﬁ-
cult to detect but may also inﬂuence LD patterns within
the MHC and maintenance of extended haplotypes (long
regions where multiple SNPs are perfectly correlated), as
it is envisaged that recombination is impeded or may be
lethal over an inversion interval between chromosomes
with and without the inversion. Inverted and non-inverted
copies of the region therefore evolve independently. Inver-
sions are not uncommon in the human genome (Khaja
et al., 2006) and there is evidence of inversions in this
region in mouse (t complex) so inversions could account
for the strong LD in the human MHC. So far, direct
evidence for inversions is lacking, but new scanning
methods will assist future investigation (Bansal et al.,
2007; Flores et al., 2007; Korbel et al., 2007).
Some recombination between deeply diverged MHC
haplotypes appears to have occurred relatively recently
compared to the estimated divergence times of such
haplotypes. Recombination of this type was recently
Figure 3. Simpliﬁed gene conﬁgurations in the RCCX and HLA-DRB regions on MHC reference haplotypes. The COX and QBL haplotype are 
monomodular for RCCX, whereas the PGF, SSTO and DBB haplotypes are bimodular. Each C4 gene may encode a C4A or a C4B protein. C4L and 
C4S are long and short C4 genes, respectively. 21A and 21B are CYP21A (pseudogene) and CYP21B, respectively. DRB2, DRB6, DRB7, DRB8 and 
DRB9 are pseudogenes.184 J. A. Traherne
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documented in the comparison of two complete MHC
haplotype sequences that are associated with different
diseases (Traherne et al., 2006b). The comparison showed
distribution patterns of variation across the MHC that
were similar to those of other HLA-disparate haplotypes,
apart from a near identical sequence of about 158 kb
within the class II region, consistent with relatively recent
common ancestry (<  3400 generations) (Fig.  4). Such
shared segments, as in this example, can be used to rule
out sections of the haplotype from containing sequences
that control disease speciﬁcity.
Block swapping between haplotypes provides a
footprint to trace evolution. The shared ancestral block,
which encompasses the HLA-DRB1 and HLA-DQB1
loci (DR3-DQ2), is present in a number of ethnically
diverse populations (Fig.  5). Similarly, other ancient,
highly diverged DR-DQ blocks, such as DR15-DQ6, are
also carried on diverse and widely distributed haplotypes.
This suggests that numerous highly diverged, ancestral
blocks are maintained in the population, and recombination
enables their occasional inclusion into different haplotype
backgrounds across populations, where they may be
selected in response to new disease challenges. In other
words, swapping of ancestral blocks is a potential
mechanism, whereby certain allelic combinations with
immunological advantage, in terms of HLA functions and
binding speciﬁcities for example, can spread across
haplotypes and populations.
Figure 4. A shared ancestral block between two DR3 -DQ2 MHC haplotypes. The COX and QBL haplotypes share an ~158 kb ancestral block, which 
contains the HLA-DRB2, HLA-DRB1, HLA-DQA1, HLA-DQB1 and MTCO3P1 loci. Within this block there are only 14 single nucleotide polymorphisms 
(SNPs) distinguishing the two DR3-DQ2 haplotypes, whereas there are 3808 SNPs that differ between the DR3-DQ2 haplotypes and the DR15-DQ6 
haplotype (PGF). This difference can be calculated to correlate with ~3400 generations that elapsed since the two DR3-DQ2 haplotypes separated 
vs. greater than 20 million years that separate the DR15-DQ6 haplotype from the DR3-DQ2 haplotypes. Vertical lines represent SNPs. HLA types for 
each haplotype are shown.
Figure 5. Frequencies of the DR3-DQ2 haplotype within 18 populations. The ﬁgure represents the ethnic diversity of DR3-DQ2 haplotype distribution 
(NCBI dbMHC).MHC architecture, evolution and disease 185
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Tempting as it may be to speculate that the spread of
ancestral blocks by interhaplotype exchange may have been
driven by selection, the frequency gradients between
populations of the derivative haplotypes could conceivably be
the outcome of neutral genetic drift and demographic history
(Gherman et al., 2007). Further population studies will
elucidate whether these stable ancestral sequences carry a
particular selective advantage that were key to disease
resistance or survival in the evolutionary history of humans.
Long-range haplotypes
LD varies markedly along the MHC but in general LD
decay over the region falls within the typical range of
genome distribution (Miretti et al., 2005; The Inter-
national HapMap Consortium, 2005; de Bakker et al.,
2006b). However, extensive LD is evidenced by the rela-
tively high occurrence of a handful of distinct long-range
haplotypes. These haplotypes have long been of interest
because of their prevalence and strong associations with
complex diseases, yet the mechanisms for their generation
are still unclear. Several possible explanations exist for
long-range LD, including low recombination rate and
polymorphic inversions. Another is maintenance of
functionally coordinated sets of alleles by selection. A
simpler explanation would be that strong positive
selection for a component of these haplotypes has
expanded their frequency in recent evolutionary history,
creating founder haplotypes that have had inadequate
evolutionary time to degrade.
Recent global studies using long-range haplotype (LRH)
and extended haplotype homozygosity (EHH) tests
support the hypothesis that signatures of positive
selection are present in the MHC (The International
HapMap Consortium, 2005, 2007; de Bakker et al.,
2006b; Voight et al., 2006; Sabeti et al., 2007). Interest-
ingly, MHC genes were not among the strongest signals
identiﬁed in these genome-wide studies. This observation
may reﬂect the nature of the MHC, where balancing
selection is also active and pre-existing alleles may be
recurrently selected, as well as the sensitivities of the tests;
LRH tests have limited power to detect selection on stand-
ing (pre-existing) variation and EHH tests have limited
ability to detect low frequency selective sweeps.
Two of the most frequent long-range MHC haplotypes
in Northern Europeans are the HLA haplotypes HLA-A1-
B8-C7-DR3-DQ2 (also termed AH 8.1) and HLA-A3-B7-
C7-DR15-DQ6 (the so-called ancestral DR2 haplotype).
The frequencies of these haplotypes in European Cauca-
sians are in the order of 10%, which is substantially
higher than expected (< 0.5%) based on the frequencies of
individual alleles on the haplotypes. The high sequence
similarity of long-range haplotypes suggests that their
prevalence is likely due to signiﬁcant expansions in
relatively recent times. Indeed, the AH 8.1 haplotype has
been estimated to have diverged from a single common
ancestor about 23,500 years ago (Smith et al., 2006). In
other words, the constituent alleles on these haplotypes
are in strong association probably because of recent
expansion rather than having been derived from distinct
haplotypes through multiple independent events in which
selection drove or maintained the linkage of these alleles.
This view suggests that there is not necessarily any
functional signiﬁcance to the linkage of constituent alleles
of long-range haplotypes because only one locus allele
under strong positive selection in this chromosome
interval could have been sufﬁcient to drive expansion of a
haplotype. The occurrence of a number of other extant
haplotypes that include DR3-DQ2 but have lost HLA-A1
or HLA-B8 is consistent with this theory.
The estimated ages of some common long-range
haplotypes typically fall within range of the human migra-
tion out of Africa and expansion into Europe. This has led
to theories of selective factors that acted to expand these
haplotypes, which in general relate to adaptation to new
environments, changes in nutrition, or resistance to infec-
tion during migrations (Distante et al., 2004; Moalem
et al., 2005). Although their exact anthropological origins
will be difﬁcult to determine, more precise estimates for
the period and the length of time such selection was
operating should be possible by comparative study and
phylogenetic analysis of MHC haplotypes in different
populations. The identiﬁcation of the variant(s) responsible
for the hypothetical selective events that led to expansions
could be informative. The DRB1 gene is a prime suspect
on the DR2 haplotype (Miretti et al., 2005) and it is
associated with susceptibility to multiple sclerosis and
protection from type 1 diabetes (Barcellos et al., 2006;
Nejentsev et al., 2007).
Any past survival beneﬁts of common long-range
haplotypes have come at a cost since many predispose to
inﬂammatory diseases prevalent in Westernized society,
such as type I diabetes and multiple sclerosis. The
inherently strong and long-ranging correlations (extend-
ing beyond the MHC in some instances) between alleles
on these haplotypes have limited the identiﬁcation of
haplotype-residing variants that contribute to associated
disease phenotypes. Improved resolution will likely be
achievable by applying higher-throughput sequencing and
higher-resolution SNP analysis to deﬁne the extent of
similarity between haplotypes and reﬁne boundaries of
homozygosity. In this way the evolutionary history and
associations with diseases may be traceable.
Haplotype tagging
The International HapMap Project was set up to map
human variation by characterizing LD patterns across the
whole genome (Thorisson et al., 2005; Frazer et al.,
2007). The project is enabling the selection of informative
tag SNPs that can act as surrogate markers for most com-
mon variants in human populations. This reduced set of
genetic markers provides an effective, cost-efﬁcient means
to conduct genome scans in large samples and to investi-
gate disease associations in greater detail.
The genetic complexity of the MHC necessitated a
more focused project to provide a reﬁned resource for this
critical region (de Bakker et al., 2006b). This study186 J. A. Traherne
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characterized the LD relationships between the highly
polymorphic HLA genes and background variation by
typing the classical HLA genes and > 7500 common SNPs
across the extended MHC region of 7.5 Mb in four
population samples (African, European, Chinese and
Japanese ancestry). The data add signiﬁcantly to our
knowledge of the underlying LD block structure. The
analysis also provided informative tag SNPs that capture
much of the common variation in the region to facilitate
efﬁcient ﬁne-mapping of MHC-associated disease (de
Bakker et al., 2006a). However, it remains to be assessed
how efﬁciently less common variants, haplotypes or
recombinants can be captured via the tagging approach.
With continued advancement in sequencing technology,
re-sequencing will probably continue to be a preferential
method for detecting rare variants outside HLA genes that
inﬂuence complex traits.
There is currently no knowledge of tag SNPs that can
serve as surrogates of the RCCX CNVs. However,
analysis has shown that SNPs outside the HLA genes can
be informative about HLA types (de Bakker et al.,
2006b). Hence, tags could potentially provide a simpler,
complementary approach to classical HLA typing for
matching transplant donors and patients or for prescreening
subjects for further analysis. However, several factors
make HLA tagging more challenging than tagging of
SNPs. First, balancing selection has resulted in a multitude
of HLA alleles in populations, the majority of which are
not common but collectively they account for a signiﬁcant
proportion of the genetic diversity. Furthermore, certain
forms of balancing selection, such as pathogen-driven,
generate new combinations of alleles across multiple HLA
genes. Consequently, a given HLA allele might be found
on a number of different haplotype backgrounds. These
effects, in addition to demography and genetic drift, mean
that although tagging of certain common HLA alleles in
some populations may be relatively straightforward,
selection of tags and the boundaries of haplotype blocks
are likely to differ between populations and HLA
haplotypes. However, once deﬁned, differences in LD
structure between populations can be helpful in differen-
tiating speciﬁc gene effects (Oksenberg et al., 2004).
Epistasis
In the MHC, a region of the genome where at least 30%
of genes are immune related and many share interrelated
functions, it would be surprising if extensive epistasis
were not active. This is an important consideration in
disease-mapping studies within the MHC since epistasis
can hinder the search for susceptibility loci; inherently the
effect of one locus is altered or masked by the effects of
another. However, genetic interactions can be informative
by revealing not only the nature of the mutations but
also gene function, functional redundancy and protein
interactions. A range of statistical methods can identify or
control for the presence of epistasis, although the degree
to which statistical modelling can elucidate the underlying
biological mechanism is limited. Consequently, the identi-
ﬁcation of true interactions can sometimes be better
achieved via molecular, rather than statistical approaches.
A recent study highlights the value of molecular studies
in characterizing epistatic interactions. The major candi-
date region for multiple sclerosis susceptibility comprises
alleles of two genes located 85 kb apart that show almost
complete LD in all ethnic groups studied to date, namely
HLA-DRB1*1501 and HLA-DRB5*0101. The tight
linkage between these two DR alleles might relate to the
persistence of a founder haplotype, although its occurrence
in diverse ethnic groups opposes this theory. A study using
functional analysis in humanized mice indicates that the
LD between the two alleles may be due to epistasis,
whereby one allele (DRB5*0101) modulates the severity
of the immune response activated by the second allele
(DRB1*1501) through peripheral T-cell deletion (Gregersen
et al., 2006). This particular epistatic interaction was
found to be associated with a milder form of multiple
sclerosis-like disease in mice.
Interactions of this type might prove to be a general
regulatory mechanism for modifying immune responses
and could be widespread throughout the MHC, contribut-
ing signiﬁcantly to patterns of LD. For instance, LD in the
HLA-DQB1–HLA-DQA1 region and HLA-DRB1 alle-
les could reﬂect the effects of persistent or strong selec-
tion for maintenance of preferred combinations of HLA-
DQB1, HLA-DQA1 and HLA-DRB1 alleles. Interest-
ingly, speciﬁc allele combinations of these three loci are
major determinants of predisposition to type 1 diabetes
(Koeleman et al., 2004).
In addition to epistasis internal to the MHC, there is
mounting evidence for interactions between MHC genes
and unlinked genes outside the complex resulting in
susceptibility to disease. Of prominence are HLA class I
interactions with the killer immunoglobulin receptor
(KIR) genes encoded in the leucocyte receptor complex
(LRC) on chromosome 19q13. KIRs are expressed by
natural killer (NK) cells as well as subsets of T cells and
interaction with their ligands, HLA class I molecules,
modulates both innate and adaptive immune responses.
Combinations of HLA class I and KIR variants have been
associated with pathologies as diverse as autoimmunity,
viral infections, pregnancy-related disorders and cancer
(Parham, 2005; Khakoo & Carrington, 2006). Thus,
interactions between KIR and MHC class I polymor-
phisms have probably been involved in human survival
during incidences of epidemic infections and have affected
reproduction and population expansion. These types of
selection pressures might explain the functional coevolu-
tion of KIR with diverging HLA class I molecules and why
KIR sequences, like the HLA loci, are highly polymorphic
and rapidly evolving (Guethlein et al., 2007; Martin et al.,
2007; Single et al., 2007).
Multiple factors complicate the interpretation of KIR-
HLA disease association, including (i) the extensive
polymorphism of the KIR and HLA class I ligands, (ii) the
LD between variants within each gene family, (iii) incomplete
knowledge of KIR ligands and oversimpliﬁcation of the
structural complexities of their interactions, and (iv)MHC architecture, evolution and disease 187
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limited understanding of KIR gene expression control.
Despite these complications, several points emerge from
the data. In general, KIR-HLA combinations with a
tendency towards stronger NK cell activation or lower
levels of inhibition are associated with increased risk of
autoimmune diseases but tend to be protective against
infectious diseases. On the other hand, stronger inhibitory
combinations are associated with protection against
inﬂammatory diseases and disorders in pregnancy (Fig. 6).
The data are consistent with the idea that disease sus-
ceptibility is modiﬁed by speciﬁc KIR-HLA ligand
interactions. For this reason several studies have
examined KIR and HLA class I combinations in disease
association studies. Such studies will need to be large, with
well-controlled populations, in order to be adequately
powered. In order to rule out false positives, risk variants
will likely have to undergo replication tests of validity
because of the many semi-independent tests that will have
to be considered. A recent study describing the speciﬁc
combinations of KIR3DL1 and HLA-B alleles that
inﬂuence HIV disease progression exempliﬁes the signiﬁ-
cance of KIR-HLA epistasis in disease-resistance and the
importance of distinguishing between alleles. The data
also afﬁrm a key role for NK cells in limiting HIV infec-
tion (Martin et al., 2007).
Epigenetics
Epigenetic changes refer to chemical modiﬁcations of
chromatin without alteration to the underlying DNA
sequence itself. Combinations of these changes modulate
the accessibility of regulatory DNA sequences to tran-
scriptional activators and repressors. In this way, collec-
tive gene activation and local control of gene-speciﬁc
transcription is controlled by the ‘epigenetic code’ (Bern-
stein et al., 2007). This complex regulation and interplay
are believed to have an essential role in cellular differenti-
ation, allowing cells to stably maintain different charac-
teristics despite containing the same genomic material.
It is also invoked in diverse cellular phenomena such as
chromosomal stability, gene silencing and parental
imprinting. Modiﬁcations of chromatin components
include methylation of DNA cytosine residues and post-
translational alterations to histone proteins, including
acetylation, phosphorylation and ubiquination. Such
changes are maintained when cells divide, and although
most of these features are considered dynamic through
development, some epigenetic features may display
trans-generational inheritance (Crews et al., 2007; Jirtle
& Skinner, 2007). However, since these modiﬁcations can
be inﬂuenced by endogenous and exogenous factors, the
epigenome is essentially the interface between genetics
and the environment, where the hardwired primary
genetic code is modulated by the plasticity of epigenetic
code.
To date, genetic studies of MHC-linked disease have
almost exclusively concentrated on DNA sequence dif-
ferences. However, given that a full explanation for most
MHC correlations with disease has not yet been reached,
it seems rational to consider the involvement of epigenet-
ics. Interest is heightened by several inferences; ﬁrst, the
association of epigenetic dysfunction in other parts of the
genome with human diseases (Feinberg, 2007). Second,
the fact that some MHC genes, including HLA genes, are
already known to be regulated by epigenetic events
(Wright & Ting, 2006). Also several epigenetic phenom-
ena, such as imprinting, violate Mendelian principles.
One area of focus is epigenetic modulations on HLA
and their effects on tumours. Inactivation of classical
HLA genes through DNA hypermethylation may be one
of the mechanisms through which cells create an immune
privilege and through which neoplastic cells escape
immune recognition. Conversely, transcription activation
of non-classical HLA-G through demethylation, and
resultant HLA-G protein expression, may facilitate
tumour cells to evade immunosurveillance. In accordance,
glioma cell lines expressing HLA-G are resistant to
allo-reactive lysis (Wiendl et al., 2002), and HLA-G-
positive melanoma cell lines are protected from NK cell
cytolysis (Cabestre et al., 1999). Correlation between
promoter methylation and HLA-G repression, and the
observation that a demethylating treatment reverses
promoter activity in vitro, lend credence to this hypothesis
(Mouillot et al., 2005).
As opposed to genetic alterations, epigenetic events can
be modiﬁed by pharmacological agents that induce DNA
hypomethylation or inhibit deacetlylation. Consequently,
there is interest to manipulate this system therapeutically,
for example to generate anticancer immune responses or
to dampen-down autoimmune reactions (Yoo & Jones,
2006). For example, methylation inhibitors might provide
beneﬁts in certain inﬂammatory diseases where HLA-G is
suspected to function as an inhibitory feedback signal.
However, current epigenetic treatments lack speciﬁcity.
For instance, epigenetic cancer therapies using DNA
methylation inhibitors to prevent inactivation of classical
HLA may in turn activate expression of HLA-G and thus
could favour tumour immune escape. Systematic efforts
are underway to measure speciﬁc forms of epigenetic
information throughout the genome. The Human
Epigenome Consortium is a public-private collaboration
that has initiated the Human Epigenome Project (HEP) in
order to identify and catalogue methylation variable
Figure 6. Synergy of HLA-KIR (human leucocyte antigen-killer 
immunoglobulin receptor) compound genotypes and duality between 
autoimmunity and infection. The general paradigm for HLA-KIR 
epistasis based on current disease association studies. Different HLA-
KIR combinations provide different levels of activation and inhibition of 
NK (natural killer) and T cells resulting in differing susceptibility and 
protection against infection and autoimmunity.188 J. A. Traherne
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positions (MVPs) in the human genome. The MHC was
chosen as the ﬁrst target of the project because it is highly
polymorphic, gene-rich and associated with disease. The
study investigated seven cell types (adipose, brain, breast,
lung, liver, prostate and muscle) across 32 individuals
(Rakyan et al., 2004). Over 100 000 CpG methylation
values within 253 amplicons were analysed. The second
phase of HEP comprised about 1.9 million CpG methyl-
ation values within 2524 amplicons across chromosomes
6, 20 and 22 in 43 samples (derived from 12 different
tissues) (Eckhardt et al., 2006). In both studies, the
methylation proﬁling was undertaken by high-throughput
bisulphite DNA sequencing. The combined data from
these projects have been integrated with the human
genome sequence using the ENSEMBL interface to establish
a database (www.epigenome.org), where the ﬁndings
of the MHC pilot study and the second HEP project are
publicly available. Overall, the methylation proﬁles were
similar in both studies; the MHC did not show signiﬁcantly
fewer or more amplicons that were either hypo- or
hypermethylated. In general, the two studies drew the same
three main conclusions. First, methylation levels are
bimodally distributed (the majority of amplicons being
either hypo- or relatively hypermethylated). Second, methyl-
ation proﬁles show tissue speciﬁcity. Third, many regions
display interindividual variation.
Other projects have used chromatin immunoprecipitation
(ChIP) coupled with next-generation sequencing for high-
throughput proﬁling of histone changes and delineation
of transcription factor binding across different cell types
and cellular stimuli (Barski et al., 2007; Mikkelsen et al.,
2007). Developing epigenetic resources such as these will
add another layer of information to genomic annotation,
by not only deﬁning regions that control gene activity in
cell types, but also by uncovering sites of imprinting and
allele-speciﬁc transcription. These ﬁndings will beneﬁt our
understanding of complexities of MHC gene function in
normal cellular homeostasis and disease states. In this
way, epigenetic research could provide markers for dis-
ease conditions and new targets for drug development.
It may offer new explanations in well-studied areas
such as autoimmunity, and will provide a basis for novel
approaches to research on environmental effects, nutri-
tion and ageing in complex disease. In this respect, the
ﬁnding that DNA methylation proﬁles are associated with
DNA alleles is a signiﬁcant discovery (Raval et al., 2007),
which could provide new insight into the rather in-
consistent MHC association studies in complex disease.
Epi-alleles and epihaplotypes that combine epigenetic
information with DNA sequence could provide improved
risk prediction for a disease than either of the two factors
analysed alone. Two concepts have been proposed for
integrating disease genetics and epigenetics: haplo-epitype
(hepitype) analysis (Murrell et al., 2005) and CDGE
(common disease genetic epidemiology in the context
of both genetic and epigenetic) analysis (Bjornsson et al.,
2004).
Finally, although the focus in this section has been on
how epigenetics modiﬁes gene activity, it is also of interest
that chromatin modiﬁcations have been evoked as
controlling activity of recombination and chromosome
breakpoints (Neumann & Jeffreys, 2006; Barski et al.,
2007), which could have signiﬁcant bearing on the LD
relationships within the MHC.
Regulatory RNAs
It has recently come to light that a signiﬁcant proportion
of the genome expresses non-coding RNA, and that there
is extensive overlap of transcriptional units and regulatory
elements (Kapranov et al., 2007). Some of these abundant
RNA transcripts, termed microRNA (miRNA), together
with sequence polymorphisms and epigenetic factors,
modulate gene expression at transcription and post-
transcriptional level. The regulatory properties of
miRNAs are implicated in gene coexpression, gene silenc-
ing, imprinting and DNA methylation, and are achieved
by affecting mRNA degradation and translation. Interest-
ingly, miRNAs often arise from demethylation of tandem
repeats (Lippman & Martienssen, 2004), and thus inter-
individual variability in tandem repeats could account for
differences in gene expression that result in inherited
phenotypic variability (Flanagan et al., 2006).
The emerging paradigm that genomic architecture is
not co-linear, but is instead interleaved and modular, has
clear repercussions in MHC research in terms of increased
information content, transcriptional complexity, regula-
tion of immune functioning and evolution. The involve-
ment of regulatory RNA in disease predisposition clearly
warrants more detailed investigation along with increased
scrutiny and consideration of non-coding DNA sequences.
Intriguingly, miRNAs may also function in interspecies
regulation involving viral miRNAs and host immune
system genes. A recent study shows that a miRNA encoded
by human cytomegalovirus (HCMV) during infection
reduces host cell killing by NK cells by speciﬁcally down-
regulating expression of a ‘stress-induced’ gene (MICB)
that encodes a ligand for the NK cell activating receptor
NKG2D (Stern-Ginossar et al., 2007). The miRNA-based
immunoevasion mechanism, exploited by HCMV, adds to
the many ways infectious agents have of immune evasion
(Wu et al., 2003; Wang et al., 2005; Pennini et al., 2006).
One can envisage ‘counteractive’ evolution of the host
immune defence genes in order to disrupt the interaction
of pathogen miRNA with target host genes.
As a ﬁnal point, down-regulation of host genes by inter-
action of their mRNAs with viral miRNA could lead to
novel therapeutics. Targeting these viral miRNAs might
constitute an antiviral therapy, while mimicking their role
could provide a means of immunosuppression.
A diagrammatic representation of factors discussed in
this review that may combine to inﬂuence MHC associa-
tions with complex disease phenotypes is given in Fig. 7.
Conclusion and outlook
The MHC provides a prototype for the genetic footprints
created by clusters of genes that are individually underMHC architecture, evolution and disease 189
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balancing selection and whose products functionally
interact. Epistasis may lie behind some aspects of the
MHC, such as ancient highly diverged haplotypes that
seem to be evolving independently except for ‘block
shufﬂing’. It could also be responsible for difﬁculties in
locating single gene contributions to disease in which
multiple-linked interacting genes are at work. Methods of
analysis that allow for, or exploit, the phenomenon of
epistasis are being developed and successfully applied.
Allowing for epistatic interactions may permit identiﬁca-
tion of genetic effects that might otherwise have remained
undetected.
The index of variation built from the MHC Haplotype
Project and related projects have dramatically improved
our ability to deﬁne the sequence variants within the
MHC involved in human disease. Higher-resolution
analysis of gene CNV and structural variation associated
with MHC genetic diversities in human populations
promises to provide further insights into complex diseases
and quantitative genetic traits. Technological develop-
ments will play a key role in future MHC studies. In the
very near future, next-generation sequencing platforms
are likely to identify new miRNAs and provide quantitative
tag-based gene expression data relevant to disease
phenotypes. Large-scale re-sequencing could potentially
replace tag-based WGA studies, even though the WGA
approach has become commonplace only relatively
recently. However, high-throughput re-sequencing projects
will bring new analytical challenges, especially in the
detection of functionally important but rare variants
among the background diversity.
Recent epigenetic studies provide a ﬁrst impression of
how the MHC is packaged and functionally organized to
regulate gene activities. Clearly, we have much more to
learn in mapping the MHC. It is already recognized that
chromatin domains that envelop individual gene regula-
tory regions, whole genes and groups of genes modulate
cellular activities. Perhaps a complete view of the MHC
disease involvement will require maps of chromatin
topography that characterizes the cell types involved in
disease. The net impact will be a substantially enhanced
annotation of the MHC, which will in turn dramatically
increase our ability to interpret sequence-level variations.
The projects described here are the start of another long
and fertile period of MHC research. Essentially, a truly
integrated epigenetic–genetic approach to common
disease is sought, including development of molecular
technologies to identify and screen gene regulators and
elucidate how and when transcription factors and
chromatin remodelling proteins interact with the genetic
code. Such study promises to unveil some of the mysteries
that have long shrouded the MHC, and provide future
directions for diagnostics and therapeutic interventions of
many prevalent and debilitating diseases.
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